Reduction of low molecular weight proteins under continuous renal replacement therapy in acute renal failure

Schwab, Sebastian; Zachoval, Christian; Bös, Dominik; Strassburg, Christian P.; Woitas, Rainer P.

doi:10.1007/s10157-018-1637-4

Cited by 1 publication

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…17 BTP has also been shown to be a reliable biomarker for the assessment of residual renal function in patients with end-stage renal disease. [18][19][20] ESKD patients being waitlisted for kidney transplantation are likely to spend years on the waiting list before receiving a kidney transplant. Even though renal transplantation in ESKD reduces the risk of cardiovascular complications in comparison to patients remaining on dialysis, the risk remains increased in comparison to the general population.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Pre‐transplant serum Beta Trace Protein indicates risk for post‐transplant major cardiac adverse events

et al. 2022

View full text Add to dashboard Cite

Background Beta Trace Protein (BTP) is a biomarker for residual kidney function which has been linked to cardiovascular and all‐cause mortality in haemodialysis patients. Following renal transplantation, recipients remain at increased risk for cardiovascular events compared with the general population. We aimed to determine the relationship of pre‐transplant BTP to major adverse cardiac events (MACE) in patients following kidney transplantation. Methods We included 384 patients with end‐stage renal disease who received a kidney transplant. MACE was defined as myocardial infarction (ST‐segment elevation or non‐ST‐segment elevation, stroke or transient ischemic attack), coronary artery disease requiring intervention or bypass or death for cardiovascular reason. The association between pre‐transplant serum BTP concentration and post‐transplant MACE was evaluated by Kaplan–Meier and Cox regression analyses. Results Post‐transplant MACE occurred in 70/384 patients. Pre‐transplant BTP was significantly higher in patients with post‐transplant MACE (14.36 ± 5.73 mg/l vs. 11.26 ± 5.11 mg/l; p < .01). Next to smoking (HR 1.81), age > 56.38 years (HR 1.97) and pre‐existing coronary heart disease (HR 8.23), BTP above the cut off value of 12.7 mg/l was confirmed as independent risk factor for MACE (HR 2.02, all p < .05). MACE‐free survival inversely correlated with pre‐transplant BTP levels. Conclusions Pre‐transplant serum BTP concentration may identify renal transplant recipients with higher risk of post‐transplant MACE.

show abstract

Section: Introductionmentioning

confidence: 99%

“…BTP has also been shown to be a reliable biomarker for the assessment of residual renal function in patients with end‐stage renal disease 18–20 . ESKD patients being waitlisted for kidney transplantation are likely to spend years on the waiting list before receiving a kidney transplant.…”

Section: Introductionmentioning

confidence: 99%